Abstract
Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Current Drug Targets
Title: Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists
Volume: 1 Issue: 3
Author(s): M. A. Khan, R. C. Calvert, M. E. Sullivan, C. S. Thomson, F. H. Mumtaz, R. J. Morgan and D. P. Mikhailidis
Affiliation:
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Abstract: Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Export Options
About this article
Cite this article as:
Khan A. M., Calvert C. R., Sullivan E. M., Thomson S. C., Mumtaz H. F., Morgan J. R. and Mikhailidis P. D., Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists, Current Drug Targets 2000; 1 (3) . https://dx.doi.org/10.2174/1389450003349164
DOI https://dx.doi.org/10.2174/1389450003349164 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets The Entero-Hepatic Nuclear Receptors Integrate Cholesterol, Lipid, and Bile Acid Homeostasis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews A Review on the Sex Differences in Organ and System Pathology with Alcohol Drinking
Current Drug Abuse Reviews Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches
Current Medicinal Chemistry Anthocyanins: Chemical Properties and Health Benefits: A Review
Current Nutrition & Food Science Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites
Current Alzheimer Research Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Infectious Disorders - Drug Targets Latest Advances in Hydrogel-Based Drug Delivery Systems for Optimization of Metabolic Syndrome Treatment
Current Medicinal Chemistry Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Pulmonary Hypertension secondary to Left Heart Disease
Current Vascular Pharmacology Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience